Botanix Pharmaceuticals has seen a sharp volume spike after a major share price decline, hinting at possible bottoming. While Sofdra sales are growing and funding has improved liquidity, the stock remains in a downtrend, with any recovery dependent on stronger fundamentals and a break above key resistance.
Orthocell is a regenerative medicine company expanding Remplir globally, but investors remain cautious because revenue growth is uneven, the business is still loss-making, and U.S. uptake may take time, leaving the stock a higher-risk turnaround opportunity.
Dimerix shares plunged 35–40% amid heavy selling and uncertainty around clinical updates, worsened by weak biotech sentiment. Further downside depends on results and the funding outlook, though volatility in early-stage biotech stocks suggests a potential for sharp rebounds.
CSL shares crashed after a US$5 billion impairment warning and weaker guidance shocked investors, sending the stock below A$100. Despite strong long-term fundamentals in plasma therapies, technical indicators remain bearish with heavy selling pressure still dominating the chart.
We view Telstra as a highly resilient, structurally advantaged cash-generating business within the Australian equity market, offering strong earnings quality and downside protection despite limited headline growth. Its focus on network leadership, disciplined capital management and monetisation of digital and infrastructure assets supports stable free cash flow and reliable capital returns, particularly in a softer macro environment. We believe the market continues to undervalue Telstra’s leverage to long-term data demand, the durability of its mobile economics, and the embedded optionality in InfraCo and enterprise digital services.
SportsHero (ASX: SHO) is an early-stage Australian sports gamification and media company focused on mobile-first prediction and gaming platforms across Southeast Asia, primarily Indonesia. It offers leveraged exposure to regional digital gaming growth but carries high execution, funding and profitability risk typical of small-cap platform build-outs.
